

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original) An anti-IFN- α monoclonal antibody which binds to and neutralizes a biological activity of at least IFN- α subtypes, IFN- α 1, IFN- α 2, IFN- α 4, IFN- α 5, IFN- α 8, IFN- α 10, and IFN- α 21.
2. (Withdrawn) The antibody of claim 1 which is a murine antibody.
3. (Original) The antibody of claim 1 which is a humanized antibody.
4. (Withdrawn) The antibody of claim 1 which is a human antibody.
5. (Original) The antibody of claim 1 wherein said biological activity is antiviral activity.
6. (Original) The antibody of claim 5 wherein said antibody is capable of neutralizing at least 70% of the antiviral activity of said IFN- α subtypes.
7. (Original) The antibody of claim 5 wherein said antibody is capable of neutralizing at least 80% of the antiviral activity of said IFN- α subtypes.
8. (Original) The antibody of claim 5 wherein said antibody is capable of neutralizing at least 90% of the antiviral activity of said IFN- α subtypes.
9. (Original) The antibody of claim 5 wherein said antibody is capable of neutralizing at least 99% of the antiviral activity of said IFN- α subtypes.

10. (Cancelled)

11. (Currently Amended) The antibody of claim 1 which is murine anti-human IFN- α monoclonal antibody 9F3 comprising an amino acid sequence of the monoclonal antibody produced by a hybridoma having ATCC Accession No. PTA-2917, or progeny thereof or a humanized or chimeric form thereof.

12. (Currently Amended) The antibody of claim 11 which is humanized anti-human IFN- α monoclonal antibody 9F3 version 13 (V13) comprising a light chain variable domain of SEQ ID NO:3 and a heavy chain variable domain of SEQ ID NO:5.

13. (Original) The antibody of claim 1 which binds essentially the same IFN- α epitope as the anti- IFN- α antibody produced by the hybridoma cell line deposited with ATCC on January 18, 2001 and having accession No. PTA-2917.

14. (Original) The antibody of claim 1 which is of the IgG class.

15. (Original) The antibody of claim 14 which has an IgG₁, IgG₂, IgG₃, or IgG₄ isotype.

16. (Original) The antibody of claim 1 which is an antibody fragment.

17. (Original) The antibody of claim 16 which is a Fab fragment.

18. (Original) The antibody of claim 16 which is a F(ab')₂ fragment.

19. (Original) The antibody of claim 16 which is a Fab' fragment.

20. (Currently Amended) An anti- IFN- α antibody light chain or an antigen binding

fragment thereof, comprising the following CDR's:

- (a) L1 of the formula RASQSVSTSSYSYMH (SEQ ID NO: 7);
- (b) L2 of the formula YASNLES (SEQ ID NO: 8); and
- (c) L3 of the formula QHSWGIPRTF (SEQ ID NO: 9).

21. (Currently Amended) The anti-IFN- α antibody light chain antigen binding fragment of claim 20 which is the light chain variable domain.

22. (Currently Amended) An anti-IFN- α antibody heavy chain or an antigen binding fragment thereof, comprising the following CDR's:

- (a) H1 of the formula GYTFTEYJIIH (SEQ ID NO: 10);
- (b) H2 of the formula SINPDYDITNYNQRFKG (SEQ ID NO: 11); and
- (c) H3 of the formula WISDFFDY (SEQ ID NO: 12).

23. (Currently Amended) The anti-IFN- α antibody heavy chain antigen binding fragment of claim 22 which is the heavy chain variable domain.

24. (Currently Amended) An anti- IFN- α antibody comprising

(A) at least one light chain or an antigen binding fragment thereof, comprising the following CDR's:

- (a) L1 of the formula RASQSVSTSSYSYMH (SEQ ID NO: 7);
- (b) L2 of the formula YASNLES (SEQ ID NO: 8); and
- (c) L3 of the formula QHSWGIPRTF (SEQ ID NO: 9); and

(B) at least one heavy chain or an antigen binding fragment thereof, comprising the following CDR's:

- (a) H1 of the formula GYTFTEYIIH (SEQ D NO: 10);
- (b) H2 of the formula SINPDYDITNYNQRFKG (SEQ ID NO: 11); and
- (c) H3 of the formula WISDFFDY (SEQ ID NO: 12).

25. (Original) The antibody of claim 24 having a homo-tetrameric structure composed of two disulfide-bonded antibody heavy chain-light chain pairs.
26. (Original) The antibody of claim 24 which is a linear antibody.
27. (Withdrawn) The antibody of claim 24 which is a murine antibody.
28. (Original) The antibody of claim 24 which is a chimeric antibody.
29. (Original) The antibody of claim 24 which is a humanized antibody.
30. (Withdrawn) The antibody of claim 24 which is a human antibody.
- 31-41. (Cancelled)
42. (Currently Amended) A hybridoma cell line comprising a nucleic acid molecule encoding an antibody of claim 1 according to any one of claims 31 to 38.
43. (Original) A hybridoma cell line deposited with ATCC on January 18, 2001 and having accession No. PTA-2917.
44. (Original) An antibody produced by the hybridoma cell line of claim 42.
45. (Original) A pharmaceutical composition comprising an effective amount of the antibody of claim 1 in admixture with a pharmaceutically acceptable carrier.
46. (Original) A pharmaceutical composition comprising an effective amount of the antibody of claim 11 in admixture with a pharmaceutically acceptable carrier.

47. (Original) A pharmaceutical composition comprising an effective amount of the antibody of claim 12 in admixture with a pharmaceutically acceptable carrier.

48. (Original) A pharmaceutical composition comprising an effective amount of the antibody of claim 24 in admixture with a pharmaceutically acceptable carrier.

49.-54. (Cancelled)